- Home
- RAMP vs MIRM Comparison
RAMP vs MIRM Comparison
Compare RAMP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- MIRM
- Stock Information
- Founded
- RAMP 2018
- MIRM 2018
- Country
- RAMP United States
- MIRM United States
- Employees
- RAMP N/A
- MIRM N/A
- Industry
- RAMP EDP Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- MIRM Health Care
- Exchange
- RAMP Nasdaq
- MIRM Nasdaq
- Market Cap
- RAMP 2.2B
- MIRM 2.5B
- IPO Year
- RAMP 1987
- MIRM 2019
- Fundamental
- Price
- RAMP $31.25
- MIRM $52.45
- Analyst Decision
- RAMP Buy
- MIRM Strong Buy
- Analyst Count
- RAMP 6
- MIRM 11
- Target Price
- RAMP $39.33
- MIRM $57.00
- AVG Volume (30 Days)
- RAMP 527.9K
- MIRM 504.4K
- Earning Date
- RAMP 02-05-2025
- MIRM 02-26-2025
- Dividend Yield
- RAMP N/A
- MIRM N/A
- EPS Growth
- RAMP N/A
- MIRM N/A
- EPS
- RAMP 0.00
- MIRM N/A
- Revenue
- RAMP $728,708,000.00
- MIRM $307,028,000.00
- Revenue This Year
- RAMP $14.29
- MIRM $83.04
- Revenue Next Year
- RAMP $8.61
- MIRM $27.22
- P/E Ratio
- RAMP $26,105.13
- MIRM N/A
- Revenue Growth
- RAMP 14.50
- MIRM 112.14
- 52 Week Low
- RAMP $21.45
- MIRM $23.14
- 52 Week High
- RAMP $38.00
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- RAMP 36.27
- MIRM 64.07
- Support Level
- RAMP $33.33
- MIRM $51.02
- Resistance Level
- RAMP $34.04
- MIRM $53.76
- Average True Range (ATR)
- RAMP 1.04
- MIRM 2.04
- MACD
- RAMP -0.45
- MIRM 0.03
- Stochastic Oscillator
- RAMP 1.33
- MIRM 73.31
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.